Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Nov;1(6):999-1004.
doi: 10.3892/ol.2010.170. Epub 2010 Sep 8.

Changes in 2'-deoxycytidine levels in various tissues of tumor-bearing mice

Ayano Iwazaki  1 , Kimie Imai, Kunio Nakanishi, Masanori Yoshioka
Affiliations

Changes in 2'-deoxycytidine levels in various tissues of tumor-bearing mice

Ayano Iwazaki et al. Oncol Lett. 2010 Nov.

Abstract

The nucleoside 2'-deoxycytidine (dCyd) increases in the plasma of cancer patients with poor prognoses. 5-fluorouracil (5FU) is one of the anti-cancer agents used in chemotherapy for patients whose plasma dCyd is elevated. We examined the free dCyd level in various tissues of mice, with and without tumors, and in mice with and without the administration of 5FU or of dCyd, and investigated the effects of dCyd in tumor-bearing animals. SP2/0-Ag14 mouse myeloma cells were transplanted subcutaneously into mice and 5FU or dCyd was administered intraperitoneally. Free dCyd was measured in blood and tissues by HPLC at two time points, once when mouse body weight was maximally decreased (1 day after the last administration of 5FU, day 16) and again when it returned to control level at 1 week after the last 5FU treatment (day 22). Results showed that in tumor-bearing mice, the level of dCyd (per g wet weight) increased in the spleen. The change in liver weight caused by the administration of 5FU correlated with the level of dCyd in the liver. Notably, the relative tumor volume and tumor weight was decreased in dCyd-treated animals in comparison with controls. In conclusion, the levels of dCyd were markedly altered in the tissues of the reticuloendothelial and lymphatic systems, such as liver and spleen, and dCyd apparently had the ability to inhibit tumor growth in the body.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of 5FU and dCyd on the body weight of mice.
Figure 2
Figure 2
Effect of 5FU and dCyd on the relative tumor volume.
Figure 3
Figure 3
Liver weight and dCyd levels at days 16 (A) and 22 (B). Significant differences from normal (non-tumor-bearing controls) are indicated by *P<0.05 and **P<0.01.
Figure 4
Figure 4
Spleen weight and dCyd levels at days 16 (A) and 22 (B). Significant differences from normal (non-tumor-bearing controls) are indicated by *P<0.05 and **P<0.01.
Figure 5
Figure 5
Tumor weight and dCyd levels at days 16 (A) and 22 (B).
Figure 6
Figure 6
dCyd concentrations in plasma at days 16 (A) and 22 (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ahmed WA, Ali-Din NH, Yoshioka M, EL-Merzabani M. 2′-Deoxycytidine (DCYD) as a potential biological marker for detecting acute lymphocytic leukemia and bladder cancer. J Union Arab Biol Cairo. 2003;20A:97–111.
    1. Ahmed WA, Moneer M, Abo-Shady MM, Mansour HH, Abd-El-Wahab N, Yoshioka M, EL-Merzabani M. 2′-Deoxycytidine as a potential biomarker for detection of hepatocellular carcinoma. Egyptian J Hosp Med. 2005;21:191–201.
    1. Yoshioka M, Abu-Zeid M, Kubo T, El-Merzabani M. Identification of a previously unknown compound as 2′-deoxycytidine found in the plasma of breast cancer patients under combined chemotherapy. Biol Pharm Bull. 1994;17:169–174. - PubMed
    1. Iwazaki A, Yoshioka M. 2′-Deoxycytidine decreases the anti-tumor effects of 5-fluorouracil on mouse myeloma cells. Biol Pharm Bull. 2010;33:1024–1027. - PubMed
    1. Moyer JD, Malinowski N, Ayers O. Salvage of circulating pyrimidine nucleosides by tissues of the mouse. J Biol Chem. 1985;260:2812–2818. - PubMed

LinkOut - more resources